Leukemia and Lymphoma Patients Fare Similarly After Stem Cell Transplants, Study Finds

For decades, doctors have treated T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma as two faces of the same disease. Both arise from immature T cells, the immune system’s in-training soldiers, and both are driven by the uncontrolled proliferation of lymphoblasts. The conventional distinction was largely anatomical: when the malignant cells crowd the bone marrow and spill into the blood, the condition is called leukemia; when they mass in the thymus, lymph nodes, or other tissues while sparing the marrow, it is labeled lymphoma. But a new retrospective study from China suggests that, at least when it comes to the most aggressive treatment option available, the two diagnoses deliver remarkably similar results.

The research, published in Annals of Hematology by a team led by Jiayuan Guo, Liuqing Huang, Zixuan Li, and senior authors Liping Dou, Zhenyang Gu, and Chunji Gao, examined 106 consecutive patients who underwent allogeneic hematopoietic stem cell transplantation at a single institution between January 2010 and January 2025. Of these, 71 had T-cell acute lymphoblastic leukemia and 35 had T-cell lymphoblastic lymphoma. Allogeneic transplantation, in which a patient receives blood-forming stem cells from a genetically matched donor, remains one of the most intensive therapies in medicine, replacing a patient’s entire immune and hematopoietic system with that of another person. It is typically reserved for patients with high-risk or relapsed disease, making the question of which diagnosis benefits most from the procedure clinically urgent.

The headline finding is one of equivalence. The researchers detected no statistically significant differences between the two groups in overall survival, disease-free survival, or graft-versus-host disease-free, relapse-free survival, a composite measure that captures the three main threats facing transplant recipients: death, relapse, and chronic immune complications. Nor did the cumulative incidence of relapse or the cumulative incidence of non-relapse mortality, which counts deaths from transplant-related causes such as infection and organ damage rather than from returning cancer, differ meaningfully between the leukemia and lymphoma cohorts. In multivariable analyses that adjusted for other clinical variables, the diagnosis itself was not associated with any of these outcomes.

That overall equivalence, however, conceals a more nuanced temporal story. Using time-dependent statistical models, the team found that the effect of diagnosis on survival changed over the course of follow-up. At six months after transplantation, patients with T-cell lymphoblastic lymphoma had worse overall survival than those with leukemia, with a time-specific hazard ratio of 2.41 and a 95 percent confidence interval of 1.10 to 5.28, a statistically significant difference. This early vulnerability likely reflects the particular hazards of the immediate post-transplant period, when conditioning regimens, infections, and acute immune reactions claim the greatest toll.

By 36 months, the picture had reversed. At that later time point, T-cell lymphoblastic lymphoma was associated with a lower risk of disease-free survival failure, with a hazard ratio of 0.16, and a dramatically lower risk of non-relapse mortality, with a subdistribution hazard ratio of just 0.06. In other words, lymphoma patients who survived the critical first months appeared to enjoy a safer long-term course than their leukemia counterparts. Consistent with this, the restricted mean survival time analysis, which quantifies average survival over a fixed window, showed that the 36-month restricted mean survival time for overall survival was 5.79 months shorter in the lymphoma group, a statistically significant gap, while disease-free and graft-versus-host disease-free, relapse-free survival showed no significant differences by this measure.

The researchers also observed that moderate to severe chronic graft-versus-host disease, a debilitating condition in which donor immune cells attack the recipient’s healthy tissues, was less frequent among patients with T-cell lymphoblastic lymphoma. This difference persisted in propensity score-matched cohorts, a technique that pairs patients from the two groups with similar baseline characteristics to reduce the confounding that plagues observational comparisons. Most other outcomes, however, remained indistinguishable between the matched groups, reinforcing the central conclusion that diagnosis alone does not determine transplant success.

The study’s robustness was tested in several ways. Complete case analyses focusing on white blood cell count and lactic dehydrogenase, two markers of disease burden that are often elevated in aggressive lymphoid malignancies, did not materially change the estimates. Nor did analyses restricted to patients in complete remission with evaluable measurable residual disease, the sensitive molecular test that detects tiny quantities of malignant cells below the threshold of microscopic examination. These sensitivity analyses suggest that the equivalence finding is not an artifact of missing data or of comparing patients at different disease stages.

The scientific backdrop to this work is a quiet revolution in how these two diseases are understood. Historically unified as a single entity, T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma have been increasingly distinguished by molecular diagnostics and cytogenetic testing, which have revealed inherent differences in their genetic signatures and chromosomal profiles. Yet comparative outcome data following allogeneic transplantation had remained scarce, leaving transplant physicians without a firm evidence base for counseling patients from the two diagnostic groups. This study, spanning fifteen years of consecutive transplants, helps fill that gap.

The clinical implications are straightforward. For patients and physicians weighing the risks and benefits of allogeneic transplantation, the diagnosis of leukemia versus lymphoma should not, on its own, drive the decision. Instead, the findings suggest that other factors, such as disease status at transplant, measurable residual disease, donor type, and patient comorbidities, remain the more meaningful predictors of outcome. The early survival disadvantage seen in lymphoma patients may warrant heightened vigilance during the first six months after transplant, while the lower late non-relapse mortality offers some reassurance for long-term survivors.

The authors are careful to frame their conclusions with appropriate caution. As a single-center retrospective study of 106 patients, the analysis lacks the statistical power of a large multicenter trial, and the time-dependent effects observed, while statistically significant, rest on modest numbers of events at each time point. The team explicitly calls for confirmation in larger multicenter studies. Still, the work represents one of the most detailed head-to-head comparisons of these two diagnoses in the transplant setting to date, and it delivers a message that is both scientifically interesting and clinically comforting: once malignant T cells drive a patient to a donor transplant, whether they first declared themselves in the marrow or in the lymph nodes may matter far less than doctors once assumed.

Subject of Research: Comparative post-transplant outcomes of T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma

Article Title: Clinical outcomes of T-cell acute lymphoblastic leukemia versus T-cell lymphoblastic lymphoma after allogeneic hematopoietic stem cell transplantation

Article References: Guo, J., Huang, L., Li, Z., Zhang, A., Li, M., Zhang, L., Wang, L., Li, F., Wang, L., Jing, Y., Bo, J., Liu, D., Dou, L., Gu, Z., & Gao, C. (2026). Clinical outcomes of T-cell acute lymphoblastic leukemia versus T-cell lymphoblastic lymphoma after allogeneic hematopoietic stem cell transplantation. Annals of Hematology. https://doi.org/10.1007/s00277-026-07295-4

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07295-4

Keywords: T-cell acute lymphoblastic leukemia, T-cell lymphoblastic lymphoma, allogeneic stem cell transplantation, overall survival, graft-versus-host disease, measurable residual disease, non-relapse mortality, propensity score matching, hematology, restricted mean survival time, relapse, Annals of Hematology